EP300 and hepatocellular carcinoma: Specifically, those patients with low ratios of Sp1/NR2E3, β‐catenin/NR2E3, or p300/NR2E3 demonstrated good clinical outcomes, suggesting multiple levels of crosstalk or interactions between NR2E3, Sp1, β‐catenin, and p300, which could either inhibit or promote HCC.